AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Orthocell (ASX:OCC) Records Strong Growth in 2024
October 07, 2024 03:10 PM AEDT| By Team Kalkine MediaHighlights,Orthocell,achieved record revenue of A$2.03 million in Q3 2024.,Demand for key products Striate+ and,Remplir,continues to drive growth.,US FDA approval for,Remplir,could unlock a,$1.6 billion,nerve repair market.,Orthocell Ltd (ASX:OCC), a...
Mesoblast (ASX:MSB) Poised for Breakthrough as FDA Decision Nears
October 07, 2024 01:32 PM AEDT| By Team Kalkine MediaHighlights,Mesoblast shares have risen by 65% in the past month.,FDA approval for its stem-cell therapy,Ryoncil,is expected soon.,Mesoblast is advancing six programs in phase III clinical trials.,Mesoblast Limited (ASX:MSB), a leader in stem-cell the...
Cochlear Limited (ASX:COH) Sees Revised Valuation Amid Market Shifts
October 07, 2024 01:25 PM AEDT| By Team Kalkine MediaHighlights:,Cochlear's,stock declined over 13% after the August results, leading to a,reevaluation,.,Citi analysts have revised the price target for Cochlear from $255 to $305, citing a valuation,adjustment.,**,Cochlear's,price-earnings ratio for fis...
Chimeric Therapeutics (ASX:CHM) Reports Cancer Treatment Breakthrough
October 07, 2024 12:58 PM AEDT| By Team Kalkine MediaHighlights,Chimeric Therapeutics reports a complete response in a,leukaemia,patient during its latest drug trial.,The combination of ‘CORE-NK’ and,Vactosertib,shows potential in treating advanced cancer.,The ongoing trial aims to,enrol,12 patients, w...
Neuren Pharmaceuticals (ASX:NEU) Advances FDA-Approved Phase 3 Trial
October 07, 2024 12:39 PM AEDT| By Team Kalkine MediaHighlights,Neuren,Pharmaceuticals received positive FDA feedback for its Phase 3 trial.,The trial will focus on children with Phelan-McDermid Syndrome (PMS), testing NNZ-2591.,Neuren,is preparing trial sites and service providers for the next phase.,...
Nyrada (ASX:NYR) Advances NYR-BI03 Drug with Successful Safety Study
October 07, 2024 12:05 PM AEDT| By Team Kalkine MediaHighlights,Nyrada,completed a safety study for its NYR-BI03 drug candidate.,The drug is being developed to treat stroke and traumatic brain injury (TBI).,Phase 1 human trials are expected to begin by late 2024.,Sydney-based Nyrada Inc (ASX:NYR) has t...
Immuron (ASX:IMC) Advances Research on Enteric Disease Treatment
October 07, 2024 11:17 AM AEDT| By Team Kalkine MediaHighlights,Immuron,(,ASX:IMC,) supports US military research on a new treatment for enteric diseases.,Interim trial results show limited protective efficacy against Campylobacter.,The trial does not affect,Immuron's,plans for,Travelan,® or its FDA me...
A Closer Look at Insider Transactions at Aroa Biosurgery (ASX:ARX)
October 07, 2024 10:58 AM AEDT| By Team Kalkine MediaHighlights,Insider directors of Aroa Biosurgery have recently increased their stakes in the company.,Insider purchases have been made at prices higher than the current market rate, reflecting confidence in the stock.,Insider ownership stands at 25%,...
Control Bionics (ASX:CBL) Reports Rising NDIS Approvals and New Leasing Programs
October 04, 2024 06:04 PM AEST| By Team Kalkine MediaHighlights,Control Bionics sees rising NDIS approvals after delays.,New leasing programs launched for communication devices in Australia.,Rights issue underway to support product commercialization and expansion.,After experiencing industry-wide delay...
Cochlear (ASX:COH) Shares Rebound After Citi Upgrade, Forecasts Stronger Growth
October 04, 2024 03:29 PM AEST| By Team Kalkine MediaKey Points:,Cochlear's stock rose 1.5% to AU$291.92 after Citi upgraded the stock from "sell" to "neutral.",Citi raised its price target to AU$305, citing expected revenue and profit growth, particularly in the Adults/Seniors market.,Cochlear's FY24...
Lumos Diagnostics Secures Funding for FebriDx® Diagnostic Tool Expansion
October 04, 2024 12:42 PM AEST| By Team Kalkine MediaHighlights:,Funding Achievement,:,Lumos Diagnostics Holdings Ltd (ASX: LDX, OTC: LDXHF) has secured approximately,US$2,984,571,from BARDA to advance its,FebriDx,® diagnostic tool.,Rapid Diagnostic Capabilities,:,FebriDx,®,utilizes,a fingerstick blood...
Neurotech International’s FDA Setback: Orphan Drug Status Denied for NTI164
October 04, 2024 10:19 AM AEST| By Team Kalkine MediaHighlights:,Neurotech International (,ASX:NTI,) was denied orphan drug status by the FDA for NTI164, citing concerns over the rarity of its target conditions.,The FDA questioned the distinction between PANDAS and PANS, and the prevalence data provide...
CSL Ltd's 2024 Performance and Sector Overview
October 04, 2024 10:06 AM AEST| By Team Kalkine MediaHighlights,CSL Ltd share price shows slight increase in 2024.,The Healthcare sector offers consistent revenue growth potential.,CSL operates in essential services, with a focus on long-term growth.,The share price of CSL Ltd,(ASX:CSL),, a global biot...
Lumos Diagnostics Secures $3M Funding from BARDA for FebriDx FDA Expansion
October 03, 2024 06:02 PM AEST| By Team Kalkine MediaHighlights,Lumos Diagnostics secures nearly $3 million in funding from BARDA.,The funds will support the FebriDx test’s CLIA waiver study and US FDA application.,The FebriDx test aids in distinguishing between bacterial and non-bacterial infections.,...
Island Pharma Raises $3.5M, Radiopharm Preps US Trial, Truscreen Gets WHO Nod
October 03, 2024 05:49 PM AEST| By Team Kalkine MediaHighlights,Island Pharmaceuticals raises $3.5M for its dengue fever study.,Radiopharm,Theranostics,prepares for a US cancer trial with FDA support.,Truscreen,Group receives recognition in,WHO,report for cervical cancer screening.,Island Pharmaceutica...
Cyclopharm Signs Interim Agreement with U.S. Veterans Health Administration for Technegas Supply
October 03, 2024 04:32 PM AEST| By Team Kalkine MediaCyclopharm Limited (ASX:CYC) has announced an Interim Agreement (IA) to supply the U.S. Veterans Health Administration (VA) with pharmaceutical and consumable components of Technegas. This deal marks an important milestone for Cyclopharm as it paves...
Lumos Diagnostics (ASX:LDX) Secures US Government Backing for FebriDx Test
October 03, 2024 01:42 PM AEST| By Team Kalkine MediaHighlights,Lumos Diagnostics secures US government funding for,FebriDx,test development.,Nearly US$3 million from BARDA to support clinical study and FDA submission.,FebriDx,aims to improve antibiotic use by distinguishing bacterial from non-bacteria...
4D Medical’s US Breakthrough, Clinuvel’s Global Push, and Biome’s Revenue Surge
October 01, 2024 02:54 PM AEST| By Team Kalkine MediaHighlights,4D Medical expects its first revenue from a US distribution deal with Philips this year.,Clinuvel Pharmaceuticals seeks Canadian approval for its skin disorder drug Scenesse.,Biome Australia reports record revenue growth in the latest quar...
Paragon Care (ASX: PGC) Shows Resilience Despite Unusual Profit Setback
October 01, 2024 02:39 PM AEST| By Team Kalkine MediaHighlights,Paragon Care shows strength despite lower reported profits.,AU$5.5 million in unusual items impacted the recent profit figures.,Future profit performance may improve as unusual expenses are not expected to recur.,Paragon Care Limited,(ASX:...
Sigma Healthcare (ASX:SIG) Shares Surge on Merger Update with Chemist Warehouse
October 01, 2024 02:12 PM AEST| By Team Kalkine MediaThe Sigma Healthcare Ltd (ASX:SIG) share price is experiencing a notable surge on Tuesday morning, climbing 12% to reach a 52-week high of AUD 1.62. This increase in investor interest comes on the heels of significant developments regarding Sigma's p...
Advertise your brand on Kalkine Media